Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)

Demirci, Umut; Tufan, Gulnihal; Aktas, Bilge; Balakan, Ozan; ALACACIOĞLU, AHMET; DANE, FAYSAL; ENGİN, HÜSEYİN; Kaplan, M.; Gunaydin, Yusuf; Ozdemir, Nuriye; ÜNEK, İLKAY; Karaca, Halit; Akman, Tulay; Sonmez, Ozlem; Coskun, Ugur; HARPUTLUOĞLU, HAKAN; Sevinc, Alper; Tonyali, Onder; BÜYÜKBERBER, SÜLEYMAN; BENEKLİ, MUSTAFA

doi:10.1007/s00432-013-1390-8

Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)

Demirci U., Tufan G., Aktas B., Balakan O., ALACACIOĞLU A., DANE F., ...More

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.139, no.5, pp.829-835, 2013 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 139 Issue: 5
Publication Date: 2013
Doi Number: 10.1007/s00432-013-1390-8
Journal Name: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.829-835
Keywords: Bevacizumab, Irinotecan, Recurrent disease, Malignant glioma
Dokuz Eylül University Affiliated: Yes

Abstract

The overall prognosis for recurrent malignant glioma (MG) is extremely poor, and treatment options are limited. We evaluated our multicenter retrospective experience for patients with recurrent MG administering bevacizumab and irinotecan in combination therapy.